HomepageDNA • NYSE
add
Ginkgo Bioworks
Vorige slotkoers
$Â 9,55
Dag-range
$Â 8,63 - $Â 9,16
Jaar-range
$Â 5,00 - $Â 17,58
Beurswaarde
523,50Â mln. USD
Gem. volume
976,44K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NYSE
Marktnieuws
.INX
1,57%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 38,84Â mln. | -56,39% |
Bedrijfskosten | 114,31Â mln. | -11,59% |
Netto inkomsten | -80,76Â mln. | -43,18% |
Netto winstmarge | -207,93 | -228,28% |
Winst per aandeel | — | — |
EBITDA | -88,10Â mln. | -82,09% |
Effectief belastingtarief | 0,00% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 461,86Â mln. | -25,05% |
Totale activa | 1,19Â mld. | -19,70% |
Totale passiva | 629,38Â mln. | -7,84% |
Totaal aandelenvermogen | 559,78 mln. | — |
Uitstaande aandelen | 56,84 mln. | — |
Koers-boekwaardeverhouding | 0,97 | — |
Rendement op activa | -18,24% | — |
Rendement op kapitaal | -21,80% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -80,76Â mln. | -43,18% |
Operationele kasstroom | -31,61Â mln. | 69,46% |
Kasstroom uit beleggingen | -72,82Â mln. | -613,88% |
Kasstroom uit financiering | 9,94Â mln. | 2.237,20% |
Nettomutatie in liquide middelen | -94,39Â mln. | 17,35% |
Vrije kasstroom | 514,00K | 100,83% |
Over
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
CEO
Opgericht
2008
Hoofdvestiging
Website
Werknemers
834